Serpin E1/PAI-1 Antibody (242816) [Alexa Fluor® 532]

• Reactivity: Hu
• Applications: WB, B/N, ELISA(Cap), ELISA(Det)
• Clone: 242816
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 532

Serpin E1/PAI-1 Antibody (242816) [Alexa Fluor® 532] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human Serpin E1/PAI-1
  Met1-Pro402
  Accession # P05121
• Specificity: Detects human Serpin E1 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human Serpin A1, A3, A4, A8, C1, F1, F2, I1, I2, recombinant mouse Serpin D1 or E2 is observed.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair)
  • ELISA Detection (Matched Antibody Pair)
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Serpin E1/PAI-1 Antibody (242816) [Alexa Fluor® 532]

• Endothelial plasminogen activator inhibitor
• Nexin
• PAI1
• PAI-1
• PAI1PAI-1
• PAISerpin E1
• PLANH1
• PLANH1plasminogen activator inhibitor 1
• serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogenactivator inhibitor type 1), member 1
• Serpin E1
• serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitortype 1), member 1

Background

As a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI‑1 is the principal inhibitor of urokinase‑type plasminogen activator (uPA) and tissue‑type PA (1, 2). As important regulators of extracellular matrix remodeling, uPA and PAI‑1 play a major role in many processes such as angiogenesis, tumor invasion and obesity (2‑4). For example, uPA and PAI-1 are the only tumor prognostic factors validated at the highest level of evidence with regard to their clinical utility in breast cancer (5). The human PAI-1 is initially synthesized as 402 amino acid precursor with a N‑terminal signal peptide (6, 7). PAI‑1 may exist in one of two possible conformations, designated as active or latent (8). The purified rhPAI‑1 is active against rhuPA. The heterogeneity at the N‑terminus of the purified recombinant human PAI‑1 has been observed before for both the recombinant and native proteins (9).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.